CR20140527A - Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido - Google Patents

Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido

Info

Publication number
CR20140527A
CR20140527A CR20140527A CR20140527A CR20140527A CR 20140527 A CR20140527 A CR 20140527A CR 20140527 A CR20140527 A CR 20140527A CR 20140527 A CR20140527 A CR 20140527A CR 20140527 A CR20140527 A CR 20140527A
Authority
CR
Costa Rica
Prior art keywords
methods
chelate complex
compositions
polypeptides
oligonucleotide chelate
Prior art date
Application number
CR20140527A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49581470&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CR20140527A publication Critical patent/CR20140527A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describe una composición farmacéutica que contiene un complejo de quelato de oligonucleótido y al menos un polipéptido o polipéptido pegilado. La presente descripción también describe composiciones farmacéuticas adicionales y métodos para el tratamiento de enfermedades que incluyen infecciones virales.
CR20140527A 2012-05-18 2014-11-18 Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido CR20140527A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648711P 2012-05-18 2012-05-18
US201261695035P 2012-08-30 2012-08-30
PCT/CA2013/050379 WO2013170386A1 (en) 2012-05-18 2013-05-17 Oligonucleotide chelate complex-polypeptide compositions and methods

Publications (1)

Publication Number Publication Date
CR20140527A true CR20140527A (es) 2014-12-15

Family

ID=49581470

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140527A CR20140527A (es) 2012-05-18 2014-11-18 Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido

Country Status (34)

Country Link
US (1) US9492506B2 (es)
EP (1) EP2849798B1 (es)
JP (1) JP2015517504A (es)
KR (1) KR102068109B1 (es)
CN (1) CN104349793B (es)
AU (1) AU2013262416B2 (es)
BR (1) BR112014028654A2 (es)
CA (1) CA2873529C (es)
CL (1) CL2014003134A1 (es)
CO (1) CO7131387A2 (es)
CR (1) CR20140527A (es)
CY (1) CY1124345T1 (es)
DK (1) DK2849798T3 (es)
DO (1) DOP2014000264A (es)
EA (1) EA035967B1 (es)
EC (1) ECSP14027694A (es)
ES (1) ES2873844T3 (es)
HK (1) HK1204279A1 (es)
HR (1) HRP20210840T1 (es)
HU (1) HUE054875T2 (es)
IL (1) IL235548B (es)
LT (1) LT2849798T (es)
MX (1) MX346239B (es)
MY (1) MY168778A (es)
NZ (1) NZ703095A (es)
PH (1) PH12014502551A1 (es)
PL (1) PL2849798T3 (es)
PT (1) PT2849798T (es)
RS (1) RS62030B1 (es)
SG (1) SG11201407599SA (es)
SI (1) SI2849798T1 (es)
TW (1) TWI635864B (es)
WO (1) WO2013170386A1 (es)
ZA (1) ZA201408674B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2542511T3 (es) 2007-05-11 2015-08-06 Adynxx, Inc. Expresión génica y dolor
ES2724851T3 (es) 2012-05-10 2019-09-16 Adynxx Inc Formulaciones para el suministro de principios activos
EP2890403A4 (en) 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS
KR20230070330A (ko) 2014-07-10 2023-05-22 레플리코르 인코포레이티드 B형 간염 및 d형 간염 바이러스 감염의 치료 방법
EP3626822A1 (en) 2014-08-15 2020-03-25 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
SG11202104636XA (en) * 2018-11-08 2021-06-29 Aligos Therapeutics Inc S-antigen transport inhibiting oligonucleotide polymers and methods

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2769114B2 (ja) * 1993-10-29 1998-06-25 サイクローン・ファーマシューティカルズ ミニマルｂ型肝炎感染症治療用医薬組成物
UA78726C2 (en) 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment
CN1694959B (zh) * 2002-09-13 2013-09-18 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
JP2006519235A (ja) 2003-02-26 2006-08-24 インターミューン インコーポレイティッド ポリエチレングリコール修飾インターフェロン組成物およびその使用方法
EP1677827B1 (en) * 2003-10-27 2008-12-10 Vertex Pharmaceuticals Incorporated Combinations for hcv treatment
JP2008516996A (ja) * 2004-10-19 2008-05-22 レプリコール インコーポレーティッド 抗ウイルス性オリゴヌクレオチド
WO2007022642A2 (en) * 2005-08-25 2007-03-01 Replicor Inc. Anti-inflammatory molecules and their uses
WO2007036016A1 (en) * 2005-09-29 2007-04-05 Replicor Inc. Therapeutic molecules and their uses
EP1928498A4 (en) * 2005-09-29 2009-11-11 Cell Biosciences Inc S METHOD FOR THE TREATMENT OF T-CELL DISORDERS WITH TISF
GB0715383D0 (en) * 2007-08-08 2007-09-19 Asterion Ltd Interferon
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
CA2709109A1 (en) 2007-12-13 2009-06-18 Alnylam Pharmaceuticals Inc. Methods and compositions for prevention or treatment of rsv infection
EP2268811A1 (en) 2008-03-07 2011-01-05 Santaris Pharma A/S Pharmaceutical compositions for treatment of microrna related diseases
KR101704988B1 (ko) * 2009-05-28 2017-02-08 큐알엔에이, 인크. 항바이러스 유전자에 대한 천연 안티센스 전사체의 억제에 의한 항바이러스 유전자 관련된 질환의 치료
EA201290152A1 (ru) * 2009-10-16 2012-12-28 Глаксо Груп Лимитед Антисмысловые ингибиторы вируса гепатита в (hbv)
ES2598556T3 (es) * 2010-08-20 2017-01-27 Replicor Inc. Complejos de quelatos de oligonucleótidos
EP2890403A4 (en) 2012-08-30 2016-03-09 Replicor Inc METHOD FOR THE TREATMENT OF HEPATITIS B AND HEPATITIS D INFECTIONS

Also Published As

Publication number Publication date
CN104349793B (zh) 2017-11-10
EP2849798B1 (en) 2021-04-07
HRP20210840T1 (hr) 2021-08-06
CL2014003134A1 (es) 2015-02-13
BR112014028654A2 (pt) 2017-10-10
IL235548A0 (en) 2015-01-29
US20130309201A1 (en) 2013-11-21
DK2849798T3 (da) 2021-05-31
SI2849798T1 (sl) 2021-08-31
AU2013262416A1 (en) 2014-12-18
PH12014502551B1 (en) 2015-01-21
LT2849798T (lt) 2021-08-10
EA201401278A1 (ru) 2015-04-30
NZ703095A (en) 2016-07-29
HK1204279A1 (en) 2015-11-13
PL2849798T3 (pl) 2021-10-18
PT2849798T (pt) 2021-05-18
CN104349793A (zh) 2015-02-11
EA035967B1 (ru) 2020-09-07
TW201408308A (zh) 2014-03-01
KR20150013309A (ko) 2015-02-04
CA2873529C (en) 2020-08-18
MX2014014021A (es) 2015-02-10
CO7131387A2 (es) 2014-12-01
CY1124345T1 (el) 2022-07-22
TWI635864B (zh) 2018-09-21
JP2015517504A (ja) 2015-06-22
EP2849798A1 (en) 2015-03-25
IL235548B (en) 2019-07-31
SG11201407599SA (en) 2014-12-30
KR102068109B1 (ko) 2020-01-21
DOP2014000264A (es) 2015-01-31
HUE054875T2 (hu) 2021-10-28
WO2013170386A1 (en) 2013-11-21
ES2873844T3 (es) 2021-11-04
US9492506B2 (en) 2016-11-15
ZA201408674B (en) 2016-01-27
CA2873529A1 (en) 2013-11-21
MX346239B (es) 2017-03-13
EP2849798A4 (en) 2016-03-09
AU2013262416B2 (en) 2017-05-11
RS62030B1 (sr) 2021-07-30
MY168778A (en) 2018-12-04
PH12014502551A1 (en) 2015-01-21
ECSP14027694A (es) 2015-12-31

Similar Documents

Publication Publication Date Title
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
MY165124A (en) Semifluorinated alkane compositions
BR112015024411A2 (pt) desaza-purinonas macrocíclicas para o tratamento de infeções virais
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
SV2018005621A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
DOP2016000253A (es) Nuevos compuestos
BR112014025041B8 (pt) Composição farmacêutica
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
IN2014CN00572A (es)
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112014013972A8 (pt) inibidores de hcv nssa
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
BR112015002979B8 (pt) Forma cristalina, e, composição farmacêutica
CL2015003431A1 (es) Derivados de piridona para el tratamiento de infecciones virales y enfermedades adicionales
DOP2017000115A (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
DOP2017000116A (es) Composiciones de acción prolongada de combinación y procedimientos para hepatitis c
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
CL2016001054A1 (es) Compuestos para el tratamiento de diabetes y complicaciones de enfermedades derivadas de la misma
CU20140133A7 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido